Pneumococcal polysaccharide 23-valent vaccine: Long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults

Vaccine

Volumn 30, Issue 30, 2012, Pages 4435-4444

  Grabenstein, John D ^a   Manoff, Susan B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antibody persistence; Pneumococcal vaccine; Polysaccharide vaccine; Revaccination; Streptococcus pneumoniae; Vaccine safety

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PNEUMOCOCCUS VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ASTHENIA; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MYALGIA; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; REVACCINATION; REVIEW; SEROTYPE; SKIN REDNESS; SYSTEMATIC REVIEW;

ADULT; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; PNEUMOCOCCAL VACCINES; TIME FACTORS;

EID: 84862007064     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.04.052     Document Type: Review

References (82)

1. Feikin D.R., Klugman K.P. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clinical Infectious Diseases 2002, 35(September (1)):547-555.
2. Advisory Committee on Immunization Practices Prevention of pneumococcal disease among infants and children-use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 2010, 59(RR-11):1-19. http://www.cdc.gov/mmwr/PDF/rr/rr5911.pdf.
3. Amanna I.J., Messaoudi I., Slifka M.K. Protective immunity following vaccination: how is it defined?. Human Vaccines 2008, 4(July-August):316-319.
4. Siegrist C.-A. Vaccine immunology. Vaccines 2008, 17-36. Elsevier. 5th ed. S. Plotkin, W. Orenstein, P. Offit (Eds.).
5. Pichichero M.E. Booster vaccinations: can immunologic memory outpace disease pathogenesis?. Pediatrics 2009, 124(December):1633-1641.
6. Vidor E. Evaluation of the persistence of vaccine-induced protection with human vaccines. Journal of Comparative Pathology 2010, 142(January (Suppl. (1))):S96-S101.
7. Grabenstein J.D. ImmunoFacts 2012: vaccines & immunologic drugs, 37th rev 2011, Wolters Kluwer Health, Saint Louis.
8. Cecil R.L. Effects of very early serum treatment in pneumococcus type 1 pneumonia. The Journal of the American Medical Association 1937, 108:689-692.
9. Casadevall A., Scharff M.D. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrobial Agents and Chemotherapy 1994, 38:1695-1702.
10. Musher D.M., Phan H.M., Watson D.A., Baughn R.E. Antibody to capsular polysaccharide of Streptococcus pneumoniae at the time of hospital admission for pneumococcal pneumonia. Journal of Infectious Diseases 2000, 182:158-167.
11. Control of communicable diseases manual 2008, American Public Health Association, Washington, DC. 19th ed. D.L. Heymann (Ed.).
12. Pletz M.W., Maus U., Krug N., Welte T., Lode H. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. International Journal of Antimicrobial Agents 2008, 32(Sep):199-206.
13. Manoff S.B., Liss C., Caulfield M.J., Marchese R.D., Silber J., Boslego J., et al. Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged ≧65 years. Journal of Infectious Diseases 2010, 201(February (15)):525-533.
14. Musher D.M., Manoff S.B., Liss C., McFetridge R.D., Marchese R.D., Bushnell B., et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. Journal of Infectious Diseases 2010, 201(February (15)):516-524.
15. Hammitt L.L., Bulkow L.R., Singleton R.J., Nuorti J.P., Hummel K.B., Miernyk K.M., et al. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: no evidence of hyporesponsiveness. Vaccine 2011, 29(January (19)):2287-2295.
16. Musher D.M., Manoff S.B., Liss C., McFetridge R.D., Liss C., Marchese R.D., et al. Antibody persistence 10 years after 1st and 2nd doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of 2nd and 3rd doses in older adults. Human Vaccines 2011, 7:919-928.
17. Jackson L.A., Gurtman A., van Cleeff M., Jansen K.U., Jayawardene D., Devlin C., et al. 13-valent pneumococcal conjugate vaccine (PCV13) enhances the response to subsequent PCV13 and 23-valent pneumococcal polysaccharide (PPSV23) vaccinations in adults 50 years and older. Presented at 49th Infectious Diseases Society of America, 2011.
18. Jackson L.A., Gurtman A., Greenberg R.N., Frenck R., Juergens C., Jayawardene D., et al. Vaccination of healthy adults with 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine at different intervals. Presented at 8th international symposium on pneumococci and pneumococcal diseases, Iguacu Falls 2012.
19. Artz A.S., Ershler W.B., Longo D.L. Pneumococcal vaccination and revaccination of older adults. Clinical Microbiology Reviews 2003, 16(April):308-318.
20. Baxendale H.E., Davis Z., White H.N., Spellerberg M.B., Stevenson F.K., Goldblatt D. Immunogenetic analysis of the immune response to pneumococcal polysaccharide. European Journal of Immunology 2000, 30(April):1214-1223.
21. Taillardet M., Haffar G., Mondière P., Asensio M.J., Gheit H., Burdin N., et al. The thymus-independent immunity conferred by a pneumococcal polysaccharide is mediated by long-lived plasma cells. Blood 2009, 114(November (12)):4432-4440.
22. Defrance T., Taillardet M., Genestier L. T cell-independent B cell memory. Current Opinion in Immunology 2011, 23(June):330-336.
23. Advisory Committee on Immunization Practices Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease: Advisory Committee on Immunization Practices (ACIP), 2011. Morbidity and Mortality Weekly Report 2011, 60:1018-1019. http://www.cdc.gov/mmwr/pdf/wk/mm6030.pdf.
24. Grabenstein J.D., Manoff S.B. Pneumococcal vaccines in adults: assessing the evolving evidence. Vaccine 2011, 29(37):6149-6154.
25. Pfizer Inc. Prevnar® 13 prescribing information December, 2011, Pfizer Inc., Philadelphia, [accessed 22.03.2012]. http://labeling.pfizer.com/showlabeling.aspx%3Fid=501.
26. Waites K.B., Canupp K.C., Chen Y.Y., DeVivo M.J., Nahm M.H. Revaccination of adults with spinal cord injury using the 23-valent pneumococcal polysaccharide vaccine. The Journal of Spinal Cord Medicine 2008, 31(1):53-59.
27. Anttila M., Voutilainen M., Jäntti V., Eskola J., Käyhty H. Contributions of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae. Clinical and Experimental Immunology 1999, 118:402-407.
28. Concepcion N.F., Frasch C.E. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clinical and Diagnostic Laboratory Immunology 2001, 8:266-272.
29. Kolibab K., Smithson S.L., Shriner A.K., Srivastava N., Khuder S., Westerink M.A. Immune response to pneumococcal polysaccharides 4 and 14 in elderly and young adults: antibody concentrations, avidity, and functional activity. Infection and Immunity 2005, 73(November):7477-7484.
30. Tarragó D., Aguilar L., Jansen W.T., Giménez M.J., Avellón A., Granizo J.J., et al. Dependence of correlation between antibody titres and opsonphagocytosis on pneumococcal serotype and patient morbidity in pre- and post-pneumococcal vaccination states. Clinical Microbiology and Infection 2007, 13(April):369-376.
31. Romero-Steiner S., Musher D.M., Cetron M.S., Pais L.B., Groover J.E., Fiore A.E., et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clinical Infectious Diseases 1999, 29:281-288.
32. Carlson A.J., Davidson W.L., McLean A.A., Vella P.P., Weibel R.E., Woodhour A.F., et al. Pneumococcal vaccine: dose, revaccination, and coadministration with influenza vaccine. Proceedings of the Society for Experimental Biology and Medicine 1979, 161(September):558-563.
33. Vella P.P., McLean A.A., Woodhour A.F., Weibel R.E., Hilleman M.R. Persistence of pneumococcal antibodies in human subjects following vaccination. Proceedings of the Society for Experimental Biology and Medicine 1980, 164(September):435-438.
34. Tillmann W., Burow M., Schroter W. Prophylaxis of postsplenectomy septicemia: effect of a new 17-valent pneumococcal vaccine. Monatsschrift fur Kinderheilkunde 1983, 131:848-852.
35. Mufson M.A., Krause H.E., Schiffman G. Long-term persistence of antibody following immunization with pneumococcal polysaccharide vaccine. Proceedings of the Society for Experimental Biology and Medicine 1983, 173(June):270-275.
36. Mufson M.A., Krause H.E., Schiffman G. Reactivity and antibody responses of volunteers given two or three doses of pneumococcal vaccine. Proceedings of the Society for Experimental Biology and Medicine 1984, 177(November):220-225.
37. Kraus C., Fischer S., Ansorg R., Hüttemann U. Pneumococcal antibodies (IgG, IgM) in patients with chronic obstructive lung disease 3 years after pneumococcal vaccination. Medical Microbiology and Immunology 1985, 174(1):51-58.
38. Linnemann C.C., First M.R., Schiffman G. Revaccination of renal transplant and hemodialysis recipients with pneumococcal vaccine. Archives of Internal Medicine 1986, 146(August):1554-1556.
39. Mufson M.A., Krause H.E., Schiffman G., Hughey D.F. Pneumococcal antibody levels one decade after immunization of healthy adults. American Journal of the Medical Sciences 1987, 293(May):279-284.
40. Konradsen H.B., Nielsen J.L., Pedersen F.K., Henrichsen J. Antibody persistence in splenectomized adults after pneumococcal vaccination. Scandinavian Journal of Infectious Diseases 1990, 22(6):725-727.
41. Musher D.M., Groover J.E., Rowland J.M., Watson D.A., Struewing J.B., Baughn R.E., et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination. Clinical Infectious Diseases 1993, 17(July):66-73.
42. Davidson M.D., Bulkow L.R., Grabman J., Parkinson A.J., Chamblee C., Williams W.W., et al. Immunogenicity of pneumococcal revaccination in patients with chronic disease. Archives of Internal Medicine 1994, 154:2209-2214.
43. Kumar D., Welsh B., Siegal D., Chen M.H., Humar A. Immunogenicity of pneumococcal vaccine in renal transplant recipients-three year follow-up of a randomized trial. American Journal of Transplantation 2007, 7(March):633-638.
44. Jackson L.A., Benson P., Sneller V.P., Butler J.C., Thompson R.S., Chen R.T., et al. Safety of revaccination with pneumococcal polysaccharide vaccine. The Journal of the American Medical Association 1999, 281(January (20)):243-248.
45. Törling J., Hedlund J., Konradsen H.B., Ortqvist A. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine 2003, 22(December (8)):96-103.
46. Hedlund J., Ortqvist A., Konradsen H.B., Kalin M. Recurrence of pneumonia in relation to the antibody response after pneumococcal vaccination in middle-aged and elderly adults. Scandinavian Journal of Infectious Diseases 2000, 32(3):281-286.
47. Sankilampi U., Honkanen P.O., Bloigu A., Leinonen M. Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly. The Journal of Infectious Diseases 1997, 176(October):1100-1104.
48. Santosham M., Englund J.A., McInnes P., Croll J., Thompson C.M., Croll L., et al. Safety and antibody persistence following Haemophilus influenzae type b conjugate or pneumococcal polysaccharide vaccines given before pregnancy in women of childbearing age and their infants. Pediatric Infectious Disease Journal 2001, 20:931-940.
49. Konradsen H.B. Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons. Clinical Infectious Diseases 1995, 21:616-620. [erratum 1996;22:204].
50. Lackner T.E., Hamilton R.G., Hill J.J., Davey C., Guay D.R.P. Pneumococcal polysaccharide revaccination: immunoglobulin G seroconversion, persistence, and safety in frail, chronically ill older subjects. Journal of the American Geriatrics Society 2003, 51(February):240-245.
51. Hung C.C., Chang S.Y., Su C.T., Chen Y.Y., Chang S.F., Yang C.Y., et al. A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy. HIV Medicine 2010, 11(January):54-63.
52. Rodriguez-Barradas M.C., Groover J.E., Lacke C.E., Gump D.W., Lahart C.J., Pandey J.P., et al. IgG antibody to pneumococcal capsular polysaccharide in human immunodeficiency virus-infected subjects: persistence of antibody in responders, revaccination in nonresponders, and relationship of immunoglobulin allotype to response. Journal of Infectious Diseases 1996, 173(Jun):1347-1353.
53. Borgoño J.M., McLean A.A., Vella P.P., Woodhour A.F., Canepa I., Davidson W.L., et al. Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants. Proceedings of the Society for Experimental Biology and Medicine 1978, 157:148-154.
54. Nelson K., Goldman J.A., Perlino C.A. Severe local reactions to pneumococcal vaccine. Southern Medical Journal 1980, 73(February):264-265.
55. Shih A., Quinley J., Lee T.K., Messina C.R. Assessing pneumococcal revaccination safety among New York State Medicare beneficiaries. Public Health Reports 2002, 117(March-April):164-173.
56. D'Heilly S., Bauman W.L., Nichol K.L. Safety and acceptability of pneumococcal vaccinations administered in nontraditional settings. American Journal of Infection Control 2002, 30(August):261-268.
57. Mufson M.A., Hughey D.F., Turner C.E., Schiffman G. Revaccination with pneumococcal vaccine of elderly persons 6 years after primary vaccination. Vaccine 1991, 9(June):403-407.
58. Landgren O., Björkholm M., Konradsen H.B., Söderqvist M., Nilsson B., Gustavsson A., et al. A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin's lymphoma. Journal of Internal Medicine 2004, 255(June):664-673.
59. Rodriguez R., Dyer P.D. Safety of pneumococcal revaccination. Journal of General Internal Medicine 1995, 10(September):511-512.
60. Rutherford E.J., Livengood J., Higginbotham M., Miles W.S., Koestner J., Edwards K.M., et al. Efficacy and safety of pneumococcal revaccination after splenectomy for trauma. The Journal of Trauma 1995, 39(September):448-452.
61. Cherif H., Landgren O., Konradsen H.B., Kalin M., Björkholm M. Poor antibody response to pneumococcal polysaccharide vaccination suggests increased susceptibility to pneumococcal infection in splenectomized patients with hematological diseases. Vaccine 2006, 24(January (9)):75-81.
62. Sankilampi U., Honkanen P.O., Pyhälä R., Leinonen M. Associations of prevaccination antibody levels with adverse reactions to pneumococcal and influenza vaccines administered simultaneously in the elderly. Vaccine 1997, 15(July):1133-1137.
63. Rigau-Perez J.G., Overturf G.D., Chan L.S., Weiss J., Powars D. Reactions to booster pneumococcal vaccination in patients with sickle cell disease. Pediatric Infectious Disease Journal 1983, 2:199-202.
64. Jackson L.A., Nelson J.C., Whitney C.G., Neuzil K.M., Benson P., Malais D., et al. Assessment of the safety of a third dose of pneumococcal polysaccharide vaccine in the Vaccine Safety Datalink population. Vaccine 2006, 24(January (12)):151-156.
65. Burwen D.R., La Voie L., Braun M.M., Houck P., Ball R. Evaluating adverse events after vaccination in the Medicare population. Pharmacoepidemiology and Drug Safety 2007, 16(July):753-761.
66. Walker F.J., Singleton R.J., Bulkow L.R., Strikas R.A., Butler J.C. Reactions after 3 or more doses of pneumococcal polysaccharide vaccine in adults in Alaska. Clinical Infectious Diseases 2005, 40(June (15)):1730-1735.
67. Snow R., Babish J.D., McBean A.M. Is there any connection between a second pneumonia shot and hospitalization among Medicare beneficiaries?. Public Health Reports 1995, 110:720-725.
68. Merck & Co., Inc. Pneumovax®23 prescribing information October 2011, Merck & Co., Inc., Whitehouse Station, NJ.
69. Advisory Committee on Immunization Practices Pneumococcal polysaccharide vaccine. Morbidity and Mortality Weekly Report 1997, 46(RR-8):1-24. ftp://ftp.cdc.gov/pub/Publications/mmwr/rr/rr4608.pdf.
70. Nichol K.L. Pneumococcal vaccination and revaccination in the elderly population. Journal of Infectious Diseases 2010, 201(March (01)):659-661.
71. Heidelberger M., DiLapi M.M., Siegel M., Walter A.W. Persistence of antibodies in human subjects injected with pneumococcal polysaccharides. Journal of Immunology 1950, 65(November):535-541.
72. Keller M.A., Stiehm E.R. Passive immunity in prevention and treatment of infectious diseases. Clinical Microbiology Reviews 2000, 13:602-614.
73. de Roux A., Schmöle-Thoma B., Siber R.G., Hackell J.G., Kuhnke A., Ahlers N., et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clinical Infectious Diseases 2008, 46(April (1)):1015-1023. [erratum 1488].
74. Goldblatt D., Southern J., Andrews N., Ashton L., Burbidge P., Woodgate S., et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clinical Infectious Diseases 2009, 49(November (1)):1318-1325.
75. Lazarus R., Clutterbuck E., Yu L.-M., Bowman J., Bateman E.A., Diggle L., et al. A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults. Clinical Infectious Diseases 2011, 52(March (15)):736-742.
76. Musher D.M., Rueda A.M., Nahm M.H., Graviss E.A., Rodriguez-Barradas M.C. Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. Journal of Infectious Diseases 2008, 198(October (1)):1019-1027.
77. Ortqvist A., Hedlund J., Burman L.A., Elbel E., Höfer M., Leinonen M., et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet 1998, 351(February (7)):399-403.
78. Sutliff W., Finland M. Antipneumococcic immunity reactions in individuals of different ages. Journal of Experimental Medicine 1932, 55:837-852.
79. Moberley S.A., Holden J., Tatham D.P., Andrews R.M. Vaccines for preventing pneumococcal infection in adults. Cochrane Database of Systematic Reviews 2008, (1). 10.1002/14651858.
80. Butler J.C., Breiman R.F., Campbell J.F., Lipman H.B., Broome C.V., Facklam R.R. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations. The Journal of the American Medical Association 1993, 270:1826-1831.
81. Shapiro E.D., Berg A.T., Austrian R., Schroeder D., Parcells V., Margolis A., et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. New England Journal of Medicine 1991, 325:1453-1460.
82. Mufson M.A. Antibody response of pneumococcal vaccine: need for booster dosing?. International Journal of Antimicrobial Agents 2000, 14(March):107-112.